|
1
|
Tang YD and Katz SD: Anemia in chronic
heart failure: prevalence, etiology, clinical correlates, and
treatment options. Circulation. 113:2454–2461. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Felker GM, Adams KF Jr, Gattis WA and
O’Connor CM: Anemia as a risk factor and therapeutic target in
heart failure. J Am Coll Cardiol. 44:959–966. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
van der Meer P, Voors AA, Lipsic E, van
Gilst WH and van Veldhuisen DJ: Erythropoietin in cardiovascular
diseases. Eur Heart J. 25:285–291. 2004.
|
|
4
|
Anand I, McMurray JJ, Whitmore J, Warren
M, Pham A, McCamish MA and Burton PB: Anemia and its relationship
to clinical outcome in heart failure. Circulation. 110:149–154.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Westenbrink BD, Visser FW, Voors AA,
Smilde TD, Lipsic E, Navis G, Hillege HL, van Gilst WH and van
Veldhuisen DJ: Anaemia in chronic heart failure is not only related
to impaired renal perfusion and blunted erythropoietin production,
but to fluid retention as well. Eur Heart J. 28:166–171. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Felker GM, Gattis WA, Leimberger JD, Adams
KF, Cuffe MS, Gheorghiade M and O’Connor CM: Usefulness of anemia
as a predictor of death and rehospitalization in patients with
decompensated heart failure. Am J Cardiol. 92:625–628. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kosiborod M, Smith GL, Radford MJ, Foody
JM and Krumholz HM: The prognostic importance of anemia in patients
with heart failure. Am J Med. 114:112–119. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mozaffarian D, Nye R and Levy WC: Anemia
predicts mortality in severe heart failure: the prospective
randomized amlodipine survival evaluation (PRAISE). J Am Coll
Cardiol. 41:1933–1939. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Silverberg DS, Wexler D, Blum M, Keren G,
Sheps D, Leibovitch E, Brosh D, Laniado S, Schwartz D, Yachnin T,
Shapira I, Gavish D, Baruch R, Koifman B, Kaplan C, Steinbruch S
and Iaina A: The use of subcutaneous erythropoietin and intravenous
iron for the treatment of the anemia of severe, resistant
congestive heart failure improves cardiac and renal function and
functional cardiac class, and markedly reduces hospitalizations. J
Am Coll Cardiol. 35:1737–1744. 2000. View Article : Google Scholar
|
|
10
|
Silverberg DS, Wexler D, Sheps D, Blum M,
Keren G, Baruch R, Schwartz D, Yachnin T, Steinbruch S, Shapira I,
Laniado S and Iaina A: The effect of correction of mild anemia in
severe, resistant congestive heart failure using subcutaneous
erythropoietin and intravenous iron: a randomized controlled study.
J Am Coll Cardiol. 37:1775–1780. 2001. View Article : Google Scholar
|
|
11
|
Ruifrok WP, de Boer RA, Westenbrink BD,
van Veldhuisen DJ and van Gilst WH: Erythropoietin in cardiac
disease: new features of an old drug. Eur J Pharmacol. 585:270–277.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Swedberg K, Young JB, Anand IS, Cheng S,
Desai AS, Diaz R, Maggioni AP, McMurray JJ, O’Connor C, Pfeffer MA,
Solomon SD, Sun Y, Tendera M and van Veldhuisen DJ; RED-HF
Committees; RED-HF Investigators. Treatment of anemia with
darbepoetin-alfa in systolic heart failure. N Engl J Med.
368:1210–1219. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cleland JG, Sullivan JT, Ball S, Horowitz
JD, Agoram B, Rosser D, Yates W, Tin L, Fuentealba P and Burton PB:
Once-monthly administration of darbepoetin α for the treatment of
patients with chronic heart failure and anemia: a pharmacokinetic
and pharmacodynamic investigation. J Cardiovasc Pharmacol.
46:155–161. 2005.
|
|
14
|
Kourea K, Parissis JT, Farmakis D,
Paraskevaidis I, Panou F, Filippatos G and Kremastinos DT: Effects
of darbepoetin alfa on quality of life and emotional stress in
anemic patients with chronic heart failure. Eur J Cardiovasc Prev
Rehabil. 15:365–369. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cosyns B, Velez-Roa S, Droogmans S,
Pierard LA and Lancellotti P: Effects of erythropoietin
administration on mitral regurgitation and left ventricular
remodeling in heart failure patients. Int J Cardiol. 138:306–307.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Parissis JT, Kourea K, Panou F, Farmakis
D, Paraskevaidis I, Ikonomidis I, Filippatos G and Kremastinos DT:
Effects of darbepoetin alfa on right and left ventricular systolic
and diastolic function in anemic patients with chronic heart
failure secondary to ischemic or idiopathic dilated cardiomyopathy.
Am Heart J. 155:7512008. View Article : Google Scholar
|
|
17
|
Palazzuoli A, Silverberg D, Iovine F,
Capobianco S, Giannotti G, Calabrò A, Campagna SM and Nuti R:
Erythropoietin improves anemia exercise tolerance and renal
function and reduces B-type natriuretic peptide and hospitalization
in patients with heart failure and anemia. Am Heart J.
152:10962006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ponikowski P, Anker SD, Szachniewicz J,
Okonko D, Ledwidge M, Zymlinski R, Ryan E, Wasserman SM, Baker N,
Rosser D, Rosen SD, Poole-Wilson PA, Banasiak W, Coats AJ and
McDonald K: Effect of darbepoetin alfa on exercise tolerance in
anemic patients with symptomatic chronic heart failure: a
randomized, double-blind, placebo-controlled trial. J Am Coll
Cardiol. 49:753–762. 2007. View Article : Google Scholar
|
|
19
|
van Veldhuisen DJ, Dickstein K,
Cohen-Solal A, Lok DJ, Wasserman SM, Baker N, Rosser D, Cleland JG
and Ponikowski P: Randomized, double-blind, placebo-controlled
study to evaluate the effect of two dosing regimens of darbepoetin
alfa in patients with heart failure and anaemia. Eur Heart J.
28:2208–2216. 2007.
|
|
20
|
Ghali JK, Anand IS, Abraham WT, Fonarow
GC, Greenberg B, Krum H, Massie BM, Wasserman SM, Trotman ML, Sun
Y, Knusel B and Armstrong P; Study of Anemia in Heart Failure Trial
(STAMINA-HeFT) Group. Randomized double-blind trial of darbepoetin
alfa in patients with symptomatic heart failure and anemia.
Circulation. 117:526–535. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Palazzuoli A, Silverberg DS, Calabrò A,
Spinelli T, Quatrini I, Campagna MS, Franci B and Nuti R: Beta
erythropoietin effects on ventricular remodeling, left and right
systolic function, pulmonary pressure, and hospitalizations in
patients affected with heart failure and anemia. J Cardiovasc
Pharmacol. 53:462–467. 2009. View Article : Google Scholar
|
|
22
|
Palazzuoli A, Quatrini I, Calabrò A,
Antonelli G, Caputo M, Campagna MS, Franci B and Nuti R: Anemia
correction by erythropoietin reduces BNP levels, hospitalization
rate, and NYHA class in patients with cardio-renal anemia syndrome.
Clin Exp Med. 11:43–48. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Parissis JT, Kourea K, Andreadou I,
Ikonomidis I, Markantonis S, Ioannidis K, Paraskevaidis I,
Iliodromitis E, Filippatos G and Kremastinos DT: Effects of
Darbepoetin Alfa on plasma mediators of oxidative and nitrosative
stress in anemic patients with chronic heart failure secondary to
ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol.
103:1134–1138. 2009. View Article : Google Scholar
|
|
24
|
Mancini DM, Katz SD, Lang CC, LaManca J,
Hudaihed A and Androne AS: Effect of erythropoietin on exercise
capacity in patients with moderate to severe chronic heart failure.
Circulation. 107:294–299. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chateauvieux S, Grigorakaki C, Morceau F,
Dicato M and Diederich M: Erythropoietin, erythropoiesis and
beyond. Biochem Pharmacol. 82:1291–1303. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
van der Meer P, Groenveld HF, Januzzi JL
Jr and van Veldhuisen DJ: Erythropoietin treatment in patients with
chronic heart failure: a meta-analysis. Heart. 95:1309–1314.
2009.PubMed/NCBI
|
|
27
|
Klapholz M, Abraham WT, Ghali JK,
Ponikowski P, Anker SD, Knusel B, Sun Y, Wasserman SM and van
Veldhuisen DJ: The safety and tolerability of darbepoetin alfa in
patients with anaemia and symptomatic heart failure. Eur J Heart
Fail. 11:1071–1077. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Groenveld HF, Januzzi JL, Damman K, van
Wijngaarden J, Hillege HL, van Veldhuisen DJ and van der Meer P:
Anemia and mortality in heart failure patients a systematic review
and meta-analysis. J Am Coll Cardiol. 52:818–827. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Weiss G and Goodnough LT: Anemia of
chronic disease. N Engl J Med. 352:1011–1023. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Anand IS, Chandrashekhar Y, Ferrari R,
Poole-Wilson PA and Harris PC: Pathogenesis of oedema in chronic
severe anaemia: studies of body water and sodium, renal function,
haemodynamic variables, and plasma hormones. Br Heart J.
70:357–362. 1993. View Article : Google Scholar
|
